- Lobe Sciences (LOBE) has signed an agreement with iNGENu Pty Ltd.
- iNGENu is a Contract Research Organization (CRO) based out of Australia that will design and conduct three or more clinical trials to evaluate Lobe’s proprietary psilocin analogues
- Lobe Sciences (LOBE) is a life sciences company focused on psychedelic medicines
- Lobe Sciences (LOBE) is trading steady at C$0.06 per share at 9:40 am ET
Lobe Sciences Ltd. (LOBE) has signed an agreement with iNGENu Pty Ltd.
iNGENu is a Contract Research Organization (CRO) based out of Australia that will design and conduct three or more clinical trials to evaluate Lobe’s proprietary psilocin analogues L-130 or L-131.
Lobe Sciences’ CEO, Philip Young stated that this partnership comes at a time when his company is moving its proprietary stable psilocin products into human clinical trials.
“iNGENu is an industry leading, full service CRO providing end-to-end services for companies developing cannabinoid and psychedelic drugs. We evaluated CRO’s in multiple geographies and chose iNGENu as their core values match ours and our commitment to discovering transformational therapies for multiple Central Nervous System diseases and trauma.”
Lobe delivers a patient friendly treatment plan that focuses on offering therapeutics in patients’ homes, physician’s offices or in the emergency department in a local hospital setting. Delivering a non-hallucinatory dose of proprietary compounds, over several days should enable patients and their personal doctors the opportunity to maintain their normal routine while receiving treatment, allowing significantly more people access to this new therapeutic approach.
Lobe Sciences Ltd. (LOBE) is a life sciences company focused on psychedelic medicines.
Lobe Sciences (LOBE) is trading steady at C$0.06 per share at 9:35 am ET.